Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estimulación dirigida a biomarcadores para eventos epileptiformes (BTSEE)

12 de noviembre de 2026 actualizado por: Cadence Neuroscience

Seguridad y eficacia de la estimulación dirigida a biomarcadores en la epilepsia

This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • California
      • Palo Alto, California, Estados Unidos, 94304
        • Reclutamiento
        • Lucile Packard Children's Hospital Stanford
        • Contacto:
          • Swetapadma Patnaik
          • Número de teléfono: (650) 721-1458
          • Correo electrónico: sweta@stanford.edu
        • Investigador principal:
          • Ann Hyslop Segeren, MD
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Reclutamiento
        • Mayo Clinic
        • Contacto:
        • Investigador principal:
          • Nicholas Gregg, MD
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Reclutamiento
        • Cook Children's Medical Center
        • Contacto:
        • Investigador principal:
          • M. Scott Perry, MD
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Reclutamiento
        • Seattle Children's Hospital
        • Investigador principal:
          • Hannah Goldstein, MD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

7 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria:

  1. Subject is greater than or equal to 7 years of age.
  2. Subject has focal onset seizures.
  3. Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
  4. Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
  5. Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
  6. For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
  7. Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
  8. A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
  9. Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
  10. Subject has had a brain MRI epilepsy evaluation within the past two years.
  11. Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.

Exclusion Criteria:

  1. Subject has a history of substance abuse within the preceding two years.

  2. Subject participated in another drug or device trial that may confound study results within the preceding 30 days.

  3. Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.

  4. Subject has anatomy that may interfere with electrode placement.

  5. Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.

  6. Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.

  7. Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.

  8. Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).

  9. Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.

  10. Subject has primary generalized seizures.

  11. Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:

    1. The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
    2. Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
  12. Subject, in the opinion of the Investigator, would be a poor study candidate.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tratamiento

Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Adverse event rate
Periodo de tiempo: Intervals through 7, 12, and 24 months post-implant

Determine adverse event rate, including adverse device effects and serious adverse events

Intervals through 7, 12, and 24 months post-implant

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Seizure frequency
Periodo de tiempo: Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.

Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline.

Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
Neurocognitive testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Depression testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Anxiety testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Quality of life testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Sleep testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Seizure severity testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Caregiver burden testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.
Suicidality risk testing
Periodo de tiempo: Evaluated at 7 months, 12 months, and 24 months post-implant.

Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline.

Evaluated at 7 months, 12 months, and 24 months post-implant.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de mayo de 2028

Finalización del estudio (Estimado)

1 de noviembre de 2030

Fechas de registro del estudio

Enviado por primera vez

9 de mayo de 2024

Primero enviado que cumplió con los criterios de control de calidad

17 de mayo de 2024

Publicado por primera vez (Actual)

22 de mayo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CAD2004

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .